Mersana Therapeutics's total assets for Q3 2025 were $62.69M, a decrease of -25.88% from the previous quarter. MRSN total liabilities were $122.22M for the fiscal quarter, a -11.25% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.